Plaimauer, B; Kremer Hovinga, J A; Juno, C; Wolfsegger, M J; Skalicky, S; Schmidt, M; Grillberger, L; Hasslacher, M; Knöbl, P; Ehrlich, H; Scheiflinger, F (2011). Recombinant ADAMTS13 normalizes von Willebrand factor-cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies. Journal of thrombosis and haemostasis, 9(5), pp. 936-44. Oxford: Wiley-Blackwell 10.1111/j.1538-7836.2011.04224.x
Full text not available from this repository. (Request a copy)Severe deficiency of the von Willebrand factor (VWF)-cleaving protease ADAMTS13 as observed in acquired thrombotic thrombocytopenic purpura (TTP) is caused by inhibitory and non-inhibitory autoantibodies directed against the protease. Current treatment with plasma exchange is considered to remove circulating antibodies and to concurrently replenish the deficient enzyme.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Haematology and Central Haematological Laboratory |
UniBE Contributor: |
Kremer Hovinga Strebel, Johanna Anna |
ISSN: |
1538-7836 |
Publisher: |
Wiley-Blackwell |
Language: |
English |
Submitter: |
Factscience Import |
Date Deposited: |
04 Oct 2013 14:18 |
Last Modified: |
02 Mar 2023 23:20 |
Publisher DOI: |
10.1111/j.1538-7836.2011.04224.x |
PubMed ID: |
21294825 |
Web of Science ID: |
000290340800007 |
URI: |
https://boris.unibe.ch/id/eprint/5846 (FactScience: 210699) |
Actions (login required)
 |
Edit item |